The Fly | DHTRF

Absence of Clinical Development Risk: Dri Healthcare Plc Trust invests in royalties from approved pharmaceutical products, thereby avoiding the high-risk, high-cost research and development phases inherent to traditional drug developers.

Diversified Royalty Portfolio: The company acquires royalties across multiple drugs, therapeutic areas, and product life cycles, significantly reducing reliance on any single asset and mitigating specific product risk.

Predictable Post-Approval Cash Flows: Royalties on established, approved pharmaceutical products often generate stable and predictable revenue streams, providing clear visibility into future cash generation.

Product Sales Performance Risk: The Trust's revenue is directly tied to the sales of the underlying pharmaceutical products from which it receives royalties, and any decline in these sales due to market competition, safety issues, or efficacy concerns would negatively impact income.

Patent Expiration and Loss of Exclusivity Risk: Many of the pharmaceutical assets have finite patent protection, and the expiration of patents or the loss of market exclusivity can lead to generic competition, significantly reducing product sales and subsequent royalty payments.

Regulatory and Reimbursement Risk: Changes in government regulations, drug pricing policies, or reimbursement practices by healthcare payers can adversely affect the sales volume and profitability of the underlying pharmaceutical products, thereby reducing royalty income.